Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its target price decreased by stock analysts at Oppenheimer from $60.00 to $40.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s target price points to a potential upside of 311.10% from the company’s current price.
Other analysts also recently issued reports about the stock. Chardan Capital increased their price objective on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research report on Monday, November 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $54.00 price target on shares of Intellia Therapeutics in a report on Thursday, September 19th. William Blair reissued a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. Citigroup cut their target price on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, BMO Capital Markets decreased their price target on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $51.06.
Read Our Latest Analysis on Intellia Therapeutics
Intellia Therapeutics Stock Down 3.2 %
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same period last year, the firm posted ($1.38) earnings per share. The company’s revenue was down 24.1% compared to the same quarter last year. On average, equities analysts anticipate that Intellia Therapeutics will post -5.12 EPS for the current year.
Insider Buying and Selling at Intellia Therapeutics
In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders sold 28,735 shares of company stock valued at $349,909. Insiders own 3.20% of the company’s stock.
Hedge Funds Weigh In On Intellia Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Signal Advisors Wealth LLC raised its stake in shares of Intellia Therapeutics by 59.9% in the fourth quarter. Signal Advisors Wealth LLC now owns 74,158 shares of the company’s stock worth $865,000 after buying an additional 27,782 shares during the period. AdvisorNet Financial Inc increased its holdings in Intellia Therapeutics by 96.4% in the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock worth $118,000 after acquiring an additional 4,950 shares in the last quarter. Green Alpha Advisors LLC bought a new stake in Intellia Therapeutics during the 4th quarter worth approximately $138,000. Franklin Resources Inc. lifted its holdings in Intellia Therapeutics by 10.3% during the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares in the last quarter. Finally, Sanctuary Advisors LLC boosted its position in shares of Intellia Therapeutics by 147.9% in the third quarter. Sanctuary Advisors LLC now owns 53,590 shares of the company’s stock worth $1,101,000 after purchasing an additional 31,976 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Further Reading
- Five stocks we like better than Intellia Therapeutics
- Short Selling – The Pros and Cons
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Investing in the High PE Growth Stocks
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What Investors Need to Know to Beat the Market
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.